Challenges for CTC-based. liquid biopsies: a focus on the low CTC frequency and diagnostic leukapheresis (DLA) as potential solution.

N.H. Stoecklein, J.C. Fischer, D. Niederacher, Leonardus Wendelinus Mathias Marie Terstappen

Research output: Contribution to journalArticleAcademicpeer-review

34 Citations (Scopus)

Abstract

Circulating tumor cells (CTCs) are very attractive surrogate markers for systemic cancer. Currently, major efforts are being made to use these rare cells in the sense of a liquid biopsy to gain molecular information for rational therapeutic decision-making. The advancements in molecular analyses of CTCs down to the single-cell level have been significant in recent years and some applications are ready to be used in clinical studies. As discussed in this review, a major challenge for translating such molecular CTC-based assays into the clinic is the extremely low frequency of CTCs and the associated problems of their reliable detection and isolation. A potential solution to overcome the low CTC frequency is the recently introduced diagnostic leukapheresis that permits screening of liters of blood. Discussed here are the challenges as well as the current efforts implementing this method into clinical workflows to realize more reliable liquid biopsies
Original languageEnglish
Pages (from-to)147-164
JournalExpert review of molecular diagnostics
Volume16
Issue number2
DOIs
Publication statusPublished - 16 Dec 2016

Fingerprint

Leukapheresis
Circulating Neoplastic Cells
Biopsy
Workflow
Decision Making
Biomarkers
Neoplasms

Keywords

  • METIS-313462
  • IR-98678

Cite this

@article{5f67a08246964d41a58747e3df2d27d0,
title = "Challenges for CTC-based. liquid biopsies: a focus on the low CTC frequency and diagnostic leukapheresis (DLA) as potential solution.",
abstract = "Circulating tumor cells (CTCs) are very attractive surrogate markers for systemic cancer. Currently, major efforts are being made to use these rare cells in the sense of a liquid biopsy to gain molecular information for rational therapeutic decision-making. The advancements in molecular analyses of CTCs down to the single-cell level have been significant in recent years and some applications are ready to be used in clinical studies. As discussed in this review, a major challenge for translating such molecular CTC-based assays into the clinic is the extremely low frequency of CTCs and the associated problems of their reliable detection and isolation. A potential solution to overcome the low CTC frequency is the recently introduced diagnostic leukapheresis that permits screening of liters of blood. Discussed here are the challenges as well as the current efforts implementing this method into clinical workflows to realize more reliable liquid biopsies",
keywords = "METIS-313462, IR-98678",
author = "N.H. Stoecklein and J.C. Fischer and D. Niederacher and Terstappen, {Leonardus Wendelinus Mathias Marie}",
year = "2016",
month = "12",
day = "16",
doi = "10.1586/14737159.2016.1123095",
language = "English",
volume = "16",
pages = "147--164",
journal = "Expert review of molecular diagnostics",
issn = "1473-7159",
publisher = "Taylor & Francis",
number = "2",

}

Challenges for CTC-based. liquid biopsies: a focus on the low CTC frequency and diagnostic leukapheresis (DLA) as potential solution. / Stoecklein, N.H.; Fischer, J.C.; Niederacher, D.; Terstappen, Leonardus Wendelinus Mathias Marie.

In: Expert review of molecular diagnostics, Vol. 16, No. 2, 16.12.2016, p. 147-164.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Challenges for CTC-based. liquid biopsies: a focus on the low CTC frequency and diagnostic leukapheresis (DLA) as potential solution.

AU - Stoecklein, N.H.

AU - Fischer, J.C.

AU - Niederacher, D.

AU - Terstappen, Leonardus Wendelinus Mathias Marie

PY - 2016/12/16

Y1 - 2016/12/16

N2 - Circulating tumor cells (CTCs) are very attractive surrogate markers for systemic cancer. Currently, major efforts are being made to use these rare cells in the sense of a liquid biopsy to gain molecular information for rational therapeutic decision-making. The advancements in molecular analyses of CTCs down to the single-cell level have been significant in recent years and some applications are ready to be used in clinical studies. As discussed in this review, a major challenge for translating such molecular CTC-based assays into the clinic is the extremely low frequency of CTCs and the associated problems of their reliable detection and isolation. A potential solution to overcome the low CTC frequency is the recently introduced diagnostic leukapheresis that permits screening of liters of blood. Discussed here are the challenges as well as the current efforts implementing this method into clinical workflows to realize more reliable liquid biopsies

AB - Circulating tumor cells (CTCs) are very attractive surrogate markers for systemic cancer. Currently, major efforts are being made to use these rare cells in the sense of a liquid biopsy to gain molecular information for rational therapeutic decision-making. The advancements in molecular analyses of CTCs down to the single-cell level have been significant in recent years and some applications are ready to be used in clinical studies. As discussed in this review, a major challenge for translating such molecular CTC-based assays into the clinic is the extremely low frequency of CTCs and the associated problems of their reliable detection and isolation. A potential solution to overcome the low CTC frequency is the recently introduced diagnostic leukapheresis that permits screening of liters of blood. Discussed here are the challenges as well as the current efforts implementing this method into clinical workflows to realize more reliable liquid biopsies

KW - METIS-313462

KW - IR-98678

U2 - 10.1586/14737159.2016.1123095

DO - 10.1586/14737159.2016.1123095

M3 - Article

VL - 16

SP - 147

EP - 164

JO - Expert review of molecular diagnostics

JF - Expert review of molecular diagnostics

SN - 1473-7159

IS - 2

ER -